Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


04:45 Thursday, July 16, 2020


RTTNews | Jul 16, 2020 04:45PM EDT

04:45 Thursday, July 16, 2020

|BEGINSUB|Asian Shares Tumble After Mixed China Data|ENDSUB|Asian stocks fell on Thursday as investors fretted about a second wave of coronavirus infections and the reimposition of lockdowns in the wake of fresh spikes in infections in the United States, Australia and Japan.U.S.-China tensions also remained on investors' radar. U.S. Secretary of State Mike Pompeo said the U.S. would impose visa restrictions on Chinese firms like Huawei Technologies that he accused of facilitating human rights violations.

|BEGINSUB|European Stocks Close Lower On Growth Concerns, U.S.-China Tensions|ENDSUB|European stocks rallied from the session's lows, but still ended on a negative note on Thursday amid uncertainty about pace of economic recovery despite recent fairly encouraging economic data.

|BEGINSUB|U.S. Stocks Close Mostly Lower On Disappointing Jobs Data|ENDSUB|After coming under pressure early in the session, stocks remained mostly lower throughout the trading day on Thursday. With the drop on the day, the Dow and the S&P 500 gave back ground after ending the previous session at their best closing levels in over a month.

|BEGINSUB|Stock Alert: Lion Financial Skyrockets After Launch Of TRS Service |ENDSUB|Shares of Lion Financial Group Limited (LGHL) are surging more than 123 percent or $4.22 in Thursday's morning trade at $7.64.

Lion Financial operates a trading platform in Hong Kong that offers products and services such as contract-for-difference trading, insurance agency, futures and securities brokerage, and asset management.

|BEGINSUB|Stock Alert: AC Immune Hits New 52-week High |ENDSUB|Shares of Switzerland-based AC Immune SA are surging more than 68 percent or $4.93 in Thursday's morning trade at $12.12, after earlier touching a new 52-week high of $13.00.

Thursday, AC Immune said it has initiated the second highest dosing group in its Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimers disease or AD.

For comments and feedback: contact editorial@rttnews.comCopyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC